INmune Bio is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Co. has two product platforms: dominant-negative tumor necrosis factor, which utilizes dominant-negative technology and is being developed for Alzheimer's and treatment resistant depression and cancer and an out-licensing strategy for Duchenne's Muscular Dystrophy; and Natural Killer Cell Priming Platform, which utilizes a medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation.
INMB — Key Stats (updated Friday, May 10, 10:21 AM)